Motilent
Motilent is a UK-based medical imaging software company that uses AI-powered cine MRI analysis to deliver validated, regulator-cleared quantitative motility scores for Crohn's disease, serving NHS hospitals, academic medical centers, and pharmaceutical clinical trial sponsors.
- Company typePrivate
- Founded2013
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Motilent does
Motilent is a UK-based, privately held medical imaging software company founded in 2013 and headquartered in London, focused on gastrointestinal disease assessment. The company builds AI-powered computer vision tools that convert dynamic cine MRI sequences into quantitative motility scores, with its flagship GIQuant product providing a validated, regulator-cleared objective score for Crohn's disease activity in adults and children (CE marked Class IIa, FDA Cleared Class II). Beyond GIQuant, Motilent has assembled a four-product platform: Entrolytics, an end-to-end GI imaging workflow platform for ingest, storage, viewing, quantification, and communication; Bridge, an intestinal ultrasound capture and de-identification solution that feeds into Entrolytics; and vEUA, a 3D pelvic and perineal modelling tool built from MRI for surgical planning.
The company monetizes through software licensing to healthcare institutions (NHS hospitals, academic medical centers) and through clinical trial endpoint services to pharmaceutical companies, with revenue described as subscription/recurring in nature and pricing negotiated per institution or per study rather than publicly disclosed. Go-to-market is enterprise field sales, with strong distribution leverage from a £1.2 million NIHR grant awarded in May 2022 supporting NHS-wide deployment of GIQuant and a retrospective and prospective IBD study involving over 3,400 patients.
Strategically, Motilent operates a partnership-led model anchored by UCL and Professor Stuart Taylor for clinical validation, alongside a roster of major pharmaceutical collaborators including AstraZeneca, Takeda, Johnson & Johnson, Nestlé Health Science, Dr Falk Pharma, and VectivBio, and an international research network spanning pediatric hospitals in the US (Cincinnati Children's, Children's Hospital of Philadelphia) and European academic centers (KU Leuven, Inselspital, Aalborg University Hospital). Headcount is reported in the 11-50 range, no revenue has been publicly disclosed, and the company has not raised disclosed venture equity, relying instead on grants and accelerator participation (DigitalHealth.London, 2019) alongside non-dilutive institutional funding.
Motilent firmographics
Firmographics- Name
- Motilent
- Legal name
- Motilent
- Website
- https://motilent.co.uk
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Motilent is a UK-based medical imaging software company that uses AI-powered cine MRI analysis to deliver validated, regulator-cleared quantitative motility scores for Crohn's disease, serving NHS hospitals, academic medical centers, and pharmaceutical clinical trial sponsors.
- Ownership category
- akta.pro rank
Motilent industry classification
Industry- Product category
- Medical Imaging Software
- NAICS
- Medical and Diagnostic Laboratories (62151)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
- akta.pro secondary industry
- General Gastroenterology (HLAKAEAA)
Keywords
Where Motilent is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Motilent business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Medical Software Licensing: Motilent generates revenue through licensing its medical imaging software (GIQuant, Entrolytics, Bridge, vEUA) to healthcare institutions including NHS hospitals, academic medical centers, and clinical research organizations. The software is deployed for both routine clinical practice and clinical trial applications.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Motilent product offering
Product offeringCore offering
Motilent develops and licenses medical imaging software for the gastrointestinal tract. Its flagship product GIQuant transforms subjective cine MRI sequences into a quantitative motility score for assessing Crohn's disease activity, and it is CE marked (Class IIa) and FDA Cleared (Class II) for adult and pediatric use. The portfolio also includes Entrolytics (an end-to-end GI imaging data platform), Bridge (intestinal ultrasound capture), and vEUA (3D pelvic/perineal modelling), sold to NHS hospitals, academic medical centres, pharmaceutical companies, and CROs for clinical practice and trials.
Product overview
Motilent offers a multi-product platform for gastrointestinal imaging and analysis. The core portfolio consists of four products: GIQuant (quantitative MRI motility scoring for Crohn's disease), Entrolytics (unified medical imaging platform for GI data management and collaboration), Bridge (intestinal ultrasound data capture and storage), and vEUA (3D pelvic/perineal anatomy modelling from MRI). Entrolytics serves as the central data platform that integrates with Bridge, while GIQuant and vEUA are specialized analytical tools that process MRI data into actionable clinical outputs.
Differentiator
Problem solved
Functional benefit
Brands
- Entrolytics: Secure, end-to-end medical imaging platform optimised for gastrointestinal data. Purpose-built for digestive disease combining clinical insight with multimodality data to support workflow - ingest, store, view, quantify, and communicate.
- GIQuant
- Bridge
- vEUA
Products and services
- GIQuant Software solution that transforms subjective cine MRI sequences into a quantitative motility score for the small bowel, providing a validated objective score quantifying Crohn's disease activity that can be tracked over time to support treatment decisions and clinical trials. CE marked (Class IIa) and FDA Cleared (Class II) for use in adults and children.
- Entrolytics Secure, end-to-end medical imaging platform optimised for gastrointestinal data that combines expert clinical insight with real-world multimodality data to support ingest, storage, viewing, quantification, and communication workflows for clinical practice, research, and clinical trials.
- Bridge Secure solution for capturing, storing, and sharing intestinal ultrasound (IUS) data that connects directly to ultrasound machines, automatically de-identifies patient data, and links to Entrolytics for compliant workflows supporting clinical trials, routine practice, and education.
- vEUA (Virtual Examination Under Anaesthetic) 3D modelling technology for pelvic and perineal anatomy that enables clinicians to build an anatomically representative model of the sphincters, levator plate, and fistula tracts from MRI in under two minutes, providing clear, interactive visualisation for surgical planning, colleague collaboration, and patient communication.
Quantifiable outcome
- Transforms subjective cine MRI into quantitative motility score
- +3 more outcomes
Companies that use Motilent
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Motilent technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Motilent partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and minor.
- AstraZenecacorePharmaceutical partner listed among Motilent's ecosystem partners, suggesting collaboration on clinical research or drug development support for gastrointestinal conditions.
- TakedacoreMajor pharmaceutical company specializing in gastroenterology, partnered with Motilent for IBD research and clinical trial support.
- Johnson & JohnsoncoreHealthcare conglomerate partner engaged with Motilent in the gastrointestinal medical technology ecosystem.
- Nestlé Health SciencecoreNutritional health company partner working with Motilent on gastrointestinal health solutions and research.
- UCL (University College London)coreAcademic institution led by Professor Stuart Taylor, providing clinical validation and research collaboration for GIQuant technology. Academic radiologists from UCL contribute to product development and validation.
- Great Ormond Street HospitalminorLeading pediatric hospital partner collaborating on IBD research and pediatric applications of Motilent's imaging technology.
- Cincinnati Children's HospitalminorMajor US pediatric hospital using Entrolytics for state-of-the-art IBD reporting and multi-centre clinical research collaboration.
- Children's Hospital of PhiladelphiaminorLeading US pediatric hospital partner in the Motilent ecosystem for IBD research collaborations.
- KU LeuvenminorBelgian university with research partnership in gastrointestinal imaging and Motilent technology validation.
- Inselspital (Bern University Hospital)minorSwiss university hospital partner in Motilent's international research network.
- Dr Falk PharmaminorPharmaceutical company specializing in gastroenterology, partner in Motilent's clinical research ecosystem.
- FibrotargetminorResearch partner focused on fibrostenosing Crohn's disease, aligned with Motilent's fibrostenotic Crohn's disease focus area.
- VectivBiominorBiotechnology company focused on gastrointestinal diseases, partnered with Motilent for clinical research.
- CUH (Cambridge University Hospitals)minorNHS foundation trust partner in UK healthcare research collaborations.
- IBUSminorIntestinal ultrasound organization partner supporting IUS research and Bridge product applications.
Scale indicators2 records
Recent moves6 records
Expansion highlights7 records
Motilent competitors and assessment
Company assessmentDirect peers
- Perspectum: UK-based medical-imaging AI company (also Oxford/London) developing quantitative MRI biomarkers for GI/hepatic conditions such as LiverMultiScan, sharing the same niche SaMD-plus-evidence commercialization model centered on pharma trial endpoints and NHS/US hospital deployment.
- Quibim: Valencia-based imaging-AI platform that builds CE/FDA-cleared quantitative radiology biomarkers sold to hospitals and pharma for trial endpoints, mirroring Motilent's regulatory-and-biomarker business model across multiple anatomies.
- Annalise.ai: Radiology-AI vendor offering multi-modality clinical decision-support workflow software to hospitals and imaging centers, comparable as a workflow-anchored imaging AI vendor competing for similar PACS-integrated budgets.
Broad incumbents
- Aidoc: Broad radiology-AI incumbent shipping dozens of FDA-cleared imaging algorithms into hospital PACS; represents the platform-incumbent risk Motilent faces and serves similar hospital enterprise buyers.
- RapidAI: Specialty imaging-AI vendor (initially stroke, now broader) selling workflow and quantification modules to hospital systems — a similar 'specialty imaging biomarker sold into clinical workflow' commercial pattern to Motilent's.
- Viz.ai: FDA-cleared, workflow-embedded imaging-AI vendor monetized via per-hospital subscription; comparable for its regulatory + clinical-workflow commercial playbook even though its focus is neurovascular.
- contextvision: Swedish medical-imaging analysis vendor with a long track record of OEM image-quality software embedded into modalities, representing the broader medical-imaging-AI/embedded-software category Motilent sits within.
Emerging players
- Imeka: Earlier-stage imaging-AI player developing quantitative diffusion-MRI biomarkers for CNS indications, comparable as a smaller specialty imaging biomarker company leveraging AI for a specific clinical vertical.
- Kheiron Medical Technologies: European imaging-AI company focused on breast cancer screening workflows, sharing Motilent's profile of a UK/EU-based specialty SaMD vendor pursuing NHS and European hospital adoption with multi-modality ambitions.
Others
- Arterys (Tempus): Cloud-native imaging-AI platform (now part of Tempus) offering oncology and cardiac quantification; comparable as the cloud imaging-AI infrastructure ecosystem in which Motilent's Entrolytics platform competes and partners.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
Motilent social profiles
Digital presenceMotilent compliance and trust
Trust signalCompliance2 records
Motilent financial estimates
Financial estimateRevenue estimate
Valuation estimate
Motilent leadership team
Management profileNumber of profiles
Profiles1 record
Motilent funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Motilent M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Motilent
What does Motilent do?
Motilent develops and licenses medical imaging software for the gastrointestinal tract. Its flagship product GIQuant transforms subjective cine MRI sequences into a quantitative motility score for assessing Crohn's disease activity, and it is CE marked (Class IIa) and FDA Cleared (Class II) for adult and pediatric use. The portfolio also includes Entrolytics (an end-to-end GI imaging data platform), Bridge (intestinal ultrasound capture), and vEUA (3D pelvic/perineal modelling), sold to NHS hospitals, academic medical centres, pharmaceutical companies, and CROs for clinical practice and trials.
Is Motilent a public or private company?
Motilent is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Motilent founded?
Motilent was founded in 2013. It employs 11 to 50 people.
Where is Motilent based?
Motilent is headquartered in London, United Kingdom, in the Europe region.
How does Motilent make money?
One revenue line is on record: medical Software Licensing.
Who are Motilent's main competitors?
Direct peers on record are Perspectum, Quibim and Annalise.ai. Broad incumbents are Aidoc, RapidAI, Viz.ai and contextvision. Emerging players are Imeka and Kheiron Medical Technologies. Arterys (Tempus) is listed as an others.
Does Motilent have an API?
No public API is recorded for Motilent.
What industry is Motilent in?
Motilent's product category is Medical Imaging Software. Its primary akta.pro industry code is HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers), with a secondary code of HLAKAEAA, General Gastroenterology. Its NAICS code is 62151 and its SIC code is 3841.